| 1 |
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
Marc J. van de Vijver et al. · New England Journal of Medicine
Open access |
18 Dec 2002 |
6,562 |
| 2 |
International network of cancer genome projects
Jennifer L. Jennings et al. · Nature
Open access256 authors |
13 Apr 2010 |
2,439 |
| 3 |
Defining ‘T cell exhaustion’
Christian U. Blank, W. Nicholas Haining, Werner Held et al. · Nature reviews. Immunology
ReviewOpen access |
30 Sep 2019 |
1,669 |
| 4 |
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al. · The Lancet Oncology
Open access |
24 Jun 2015 |
1,581 |
| 5 |
Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers
Myriam Chalabi et al. · Nature Medicine
Open access |
Apr 2020 |
1,437 |
| 6 |
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina Venetia Long et al. · The Lancet
|
31 May 2015 |
1,419 |
| 7 |
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Robert Judson, Jaap Verweij, Hans A. J. Gelderblom et al. · The Lancet Oncology
Open access |
5 Mar 2014 |
1,195 |
| 8 |
Direct detection of early-stage cancers using circulating tumor DNA
Jillian A. Phallen et al. · Science Translational Medicine
Open access |
16 Aug 2017 |
1,185 |
| 9 |
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Caroline Robert, Antoni Ribas, Jacob Schachter et al. · The Lancet Oncology
Open access |
22 Jul 2019 |
1,179 |
| 10 |
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
Alison J. Rodger et al. · The Lancet
Open access189 authors |
2 May 2019 |
1,029 |
| 11 |
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project
Milena Sant, Claudia Allemani, Carmen Ţereanu et al. · Blood
Open access |
27 Jul 2010 |
978 |
| 12 |
Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal
Ino de Bruijn et al. · Cancer Research
Open access |
5 Sep 2023 |
918 |
| 13 |
Patient-derived organoids can predict response to chemotherapy in metastatic colorectal cancer patients
Salo Ooft et al. · Science Translational Medicine
Open access |
9 Oct 2019 |
865 |
| 14 |
CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells
Paul Andrew Antony, Ciriaco A. Piccirillo, Akgül Akpınarlı et al. · The Journal of Immunology
Open access |
Mar 2005 |
754 |
| 15 |
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
Paolo A. Ascierto, Dirk Schadendorf, Carola Berking et al. · The Lancet Oncology
|
12 Feb 2013 |
647 |
| 16 |
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
Adrianus Johannes De Langen et al. · The Lancet
Open access |
7 Feb 2023 |
609 |
| 17 |
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
Ben J. Slotman, Harm van Tinteren, John O. Praag et al. · The Lancet
Open access |
15 Sep 2014 |
607 |
| 18 |
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer
Ryan Bruce Corcoran et al. · Cancer Discovery
Open access |
8 Feb 2018 |
599 |
| 19 |
Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial
Penella J. Woll, Peter Reichardt, Axel Le Cesne et al. · The Lancet Oncology
|
3 Sep 2012 |
596 |
| 20 |
Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice
Paul Krimpenfort, Kim C. Quon, Wolter J. Mooi et al. · Nature
|
Sep 2001 |
594 |
| 21 |
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza, David Cibula, Ana Oaknin Benzaquen et al. · The Lancet Oncology
|
3 Dec 2014 |
554 |
| 22 |
Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products.
Nico J. Stam, Hergen Spits, Hidde L. Ploegh · The Journal of Immunology
|
Oct 1986 |
547 |
| 23 |
Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Alexander Martens et al. · Clinical Cancer Research
Open access |
19 Jan 2016 |
546 |
| 24 |
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
Thomas Powles et al. · The Lancet Oncology
Open access227 authors |
21 Sep 2020 |
509 |
| 25 |
Physical Activity and Breast Cancer
Evelyn M. Monninkhof, Sjoerd Geert Elias, Femke A. Vlems et al. · Epidemiology
|
22 Nov 2006 |
504 |
| 26 |
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial
Evan W. Alley, Juanita Suzanne Lopez, Armando Santoro et al. · The Lancet Oncology
|
10 Mar 2017 |
493 |
| 27 |
Mesothelioma: Scientific clues for prevention, diagnosis, and therapy
Michele Carbone et al. · CA A Cancer Journal for Clinicians
Open access |
8 Jul 2019 |
464 |
| 28 |
Isolated Limb Perfusion with Tumor Necrosis Factor and Melphalan for Limb Salvage in 186 Patients with Locally Advanced Soft Tissue Extremity Sarcomas
Alexander M.M. Eggermont, Heimen Schraffordt Koops, Joseph M. Klausner et al. · Annals of Surgery
Open access |
Dec 1996 |
460 |
| 29 |
Pancreatic cancer
Thomas F. Stoop, Ammar A. Javed, Atsushi Oba et al. · The Lancet
Open access |
Apr 2025 |
452 |
| 30 |
Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes
José M. C. Tubío et al. · Science
Open access |
31 Jul 2014 |
446 |
| 31 |
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement
Jesús Esquivel et al. · Annals of Surgical Oncology
|
27 Oct 2006 |
433 |
| 32 |
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
Joaquim Bellmunt et al. · The Lancet Oncology
Open access |
14 Mar 2021 |
431 |
| 33 |
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
Andrew Gordon Nicholson et al. · Journal of Thoracic Oncology
Open access152 authors |
24 Dec 2015 |
429 |
| 34 |
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andres M. Poveda et al. · The Lancet Oncology
Open access123 authors |
20 Mar 2021 |
427 |
| 35 |
Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking
Linda V. Sinclair, David K. Finlay, Carmen Gloria Feijóo et al. · Nature Immunology
Open access |
6 Apr 2008 |
396 |
| 36 |
Federated learning enables big data for rare cancer boundary detection
Sarthak Pati et al. · Nature Communications
Open access279 authors |
5 Dec 2022 |
390 |
| 37 |
Randomized phase II trial of gemcitabine–cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer
Ulrich Gatzemeier, G. Groth, Charles Andrew Butts et al. · Annals of Oncology
Open access |
19 Dec 2003 |
387 |
| 38 |
Mfn2 ubiquitination by PINK1/parkin gates the p97-dependent release of ER from mitochondria to drive mitophagy
Gian‐Luca McLelland, Thomas Goiran, Wei Yi et al. · eLife
Open access |
20 Apr 2018 |
386 |
| 39 |
Self-Recognition of Cd1 by γ/δ T Cells
Franca M. Spada, Ethan P. Grant, Peter J. Peters et al. · The Journal of Experimental Medicine
Open access |
13 Mar 2000 |
378 |
| 40 |
Differential Development of Murine Dendritic Cells by GM-CSF versus Flt3 Ligand Has Implications for Inflammation and Trafficking
Yuekang Xu, Yifan Zhan, Andrew M. Lew et al. · The Journal of Immunology
|
Dec 2007 |
375 |
| 41 |
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age
Martine J Piccart et al. · The Lancet Oncology
Open access |
14 Mar 2021 |
373 |
| 42 |
Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatment
Fred H. Menko, Eamonn Richard Maher, Laura S. Schmidt et al. · Familial Cancer
Open access |
10 Jul 2014 |
368 |
| 43 |
Live Tracking of Inter-organ Communication by Endogenous Exosomes In Vivo
Frederik J. Verweij, Céline Revenu, Guillaume Arras et al. · Developmental Cell
Open access |
Feb 2019 |
352 |
| 44 |
The general public’s information needs and perceptions regarding hereditary cancer: an application of the Integrated Change Model
Hein de Vries, Ilse Mesters, Hermanna van de Steeg et al. · Patient Education and Counseling
|
8 Jun 2004 |
340 |
| 45 |
An exercise-inducible metabolite that suppresses feeding and obesity
Veronica L. Li et al. · Nature
Open access |
15 Jun 2022 |
332 |
| 46 |
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review
DAVID M. GILLIGAN, Marianne C. Nicolson, Ian Smith et al. · The Lancet
Review |
Jun 2007 |
326 |
| 47 |
Primary T Cell Expansion and Differentiation In Vivo Requires Antigen Presentation by B Cells
Alison Crawford, Megan K. L. MacLeod, Ton N. Schumacher et al. · The Journal of Immunology
Open access |
Mar 2006 |
318 |
| 48 |
Translation procedures for standardised quality of life questionnaires: The European Organisation for Research and Treatment of Cancer (EORTC) approach
Michael T Koller, Neil K. Aaronson, Jane M. Blazeby et al. · European Journal of Cancer
|
Aug 2007 |
304 |
| 49 |
Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary
Thomas Steinmüller, Réza Kianmanesh, Massimo Falconi et al. · Neuroendocrinology
Open access |
21 Nov 2007 |
296 |
| 50 |
Correcting for Lead Time and Length Bias in Estimating the Effect of Screen Detection on Cancer Survival
Stephen William Duffy, Irıs D. Nagtegaal, Matthew Wallis et al. · American Journal of Epidemiology
|
13 May 2008 |
290 |